

Visit Our Web Site At:
www.canjneurosci.org

THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

93 Editorial – Stereotactic Radiosurgery

NJ Lapierre and M Bernstein

REVIEW ARTICLE

95 Temporal Lobe Epilepsy Surgery in Childhood: Rationale for Greater Use

Warren T Blume

ORIGINAL ARTICLES

99 Radiosurgery for Arteriovenous Malformations: the University of Toronto Experience

C Young, R Summerfield, M Schwartz, P O'Brien and R Ramani

106 Prediction of Obliteration of Arteriovenous Malformations after Radiosurgery: the Obliteration Prediction Index

*Michael Schwartz, Katharina Sixel, Charlene Young, Andras Kemeny,
David Forster, Lee Walton and Edmee Franssen*

110 Radiosurgery and Accelerated Radiotherapy for Patients with Glioblastoma

G Shenouda, L Souhami, EB Podgorsak, JP Bahary, JG Villemure, JL Caron and G Mohr

116 Somatosensory Evoked Potential Identification of Sensorimotor Cortex in Removal of Intracranial Neoplasms

David W Rowed, David A Houlden and Devsur G Basavakumar

121 Neuropathological Changes in Chronic Adult Hydrocephalus: Cortical Biopsies and Autopsy Findings

Marc R Del Bigio, Erico R Cardoso and William C Halliday

127 "Familial Parkinson's Disease" – A Case-Control Study of Families

Ryan J Uitti, Hitoshi Shinotoh, Margo Hayward, Michael Schulzer, Edwin Mak and Donald B Calne

133 Pallidomy Increases Cortical Inhibition in Parkinson's Disease

A Strafella, P Ashby, A Lozano and AE Lang

137 Varicella Zoster Antibodies after Herpes Zoster, Varicella and Multiple Sclerosis

RT Ross, LE Nicolle, MR Dawood, Mary Cheang and C Feschuk

140 A Randomized, Controlled Trial of Linopirdine in the Treatment of Alzheimer's Disease

*Kenneth Rockwood, B Lynn Beattie, M Robin Eastwood, Howard Feldman, Erich Mohr,
William Pryse-Phillips and Serge Gauthier*

146 A Rare Form of Adult Onset Leukodystrophy: Orthochromatic Leukodystrophy with Pigmented Glia

P Shannon, JR Wherrett and S Nag

151 Tissue Plasminogen Activator in a Vertebral Artery Dissection

Andrew P Gasecki, Carmelo Graffagnino and Vladimir Hachinski

155 Lhermitte-Duclos Disease: Literature Review and Novel Treatment Strategy

Sagun Tuli, John P Provias and Mark Bernstein

161 Current Management of Aneurysmal Subarachnoid Hemorrhage: Guidelines from the Canadian Neurosurgical Society

JM Findlay and a Canadian Neurosurgical Society practice guidelines review group

(complete contents page i)

32nd CANADIAN
CONGRESS OF
NEUROLOGICAL
SCIENCES

June 24 - 28, 1997

Saskatoon, Saskatchewan

*The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society,
The Canadian Society of Clinical Neurophysiologists, The Canadian Association for Child Neurology*

With Epival, it can be.



Epival has been proven effective in primary generalized epilepsy,¹⁻³ as well as in partial seizures that secondarily generalize.^{4,5*} Just as importantly, Epival has been associated with little effect on learning and cognition,⁶ and is generally well tolerated in properly screened patients.^{7†}



Because as your epilepsy patients can confirm, there's more to anticonvulsant therapy than seizure control.

**THIS SHOULD BE THE ONLY
INDICATION THEY HAVE EPILEPSY.**





Epival[®]
(divalproex sodium)

HELPS PUT PATIENTS BACK IN CONTROL.

* For use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal and is useful in primary generalized seizures with tonic-clonic manifestations. Epival may also be used adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures.

† Monitoring of hepatic function and blood coagulation is advised. Caution is advised in children < 10 years on multiple AEDs.

 PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
SAINTE-LAURENT, QUEBEC H4R 1Z1

© Abbott Laboratories, Limited 
Product Monograph available on request.

For brief prescribing information see pages xxii, xxiii.

Visit Our Web Site At:
www.canjneurolsci.org

THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

- 93 Editorial – Stereotactic Radiosurgery
NJ Lapierre and M Bernstein
- REVIEW ARTICLE 95 Temporal Lobe Epilepsy Surgery in Childhood: Rationale for Greater Use
Warren T Blume
- ORIGINAL ARTICLES 99 Radiosurgery for Arteriovenous Malformations: the University of Toronto Experience
C Young, R Summerfield, M Schwartz, P O'Brien and R. Ramani
- 106 Prediction of Obliteration of Arteriovenous Malformations after Radiosurgery: the Obliteration Prediction Index
Michael Schwartz, Katharina Sixel, Charlene Young, Andras Kemeny, David Forster, Lee Walton and Edmee Franssen
- 110 Radiosurgery and Accelerated Radiotherapy for Patients with Glioblastoma
G Shenouda, L Souhami, EB Podgorsak, JP Bahary, JG Villemure, JL Caron and G Mohr
- 116 Somatosensory Evoked Potential Identification of Sensorimotor Cortex in Removal of Intracranial Neoplasms
David W Rowed, David A Houlden and Devsur G Basavakumar
- 121 Neuropathological Changes in Chronic Adult Hydrocephalus: Cortical Biopsies and Autopsy Findings
Marc R Del Bigio, Erico R Cardoso and William C Halliday
- 127 “Familial Parkinson’s Disease” – A Case-Control Study of Families
Ryan J Uitti, Hitoshi Shinotoh, Margo Hayward, Michael Schulzer, Edwin Mak and Donald B Calne
- 133 Pallidomy Increases Cortical Inhibition in Parkinson’s Disease
A Strafella, P Ashby, A Lozano and AE Lang
- 137 Varicella Zoster Antibodies after Herpes Zoster, Varicella and Multiple Sclerosis
RT Ross, LE Nicolle, MR Dawood, Mary Cheang and C Feschuk
- 140 A Randomized, Controlled Trial of Linopirdine in the Treatment of Alzheimer’s Disease
Kenneth Rockwood, B Lynn Beattie, M Robin Eastwood, Howard Feldman, Erich Mohr, William Pryse-Phillips and Serge Gauthier
- 146 A Rare Form of Adult Onset Leukodystrophy: Orthochromatic Leukodystrophy with Pigmented Glia
P Shannon, JR Wherrett and S Nag
- 151 Tissue Plasminogen Activator in a Vertebral Artery Dissection
Andrew P Gasecki, Carmelo Graffagnino and Vladimir Hachinski
- 155 Lhermitte-Duclos Disease: Literature Review and Novel Treatment Strategy
Sagun Tuli, John P Provias and Mark Bernstein
- NEUROSURGICAL PRACTICE 161 Current Management of Aneurysmal Subarachnoid Hemorrhage: Guidelines from the Canadian Neurosurgical Society
JM Findlay and a Canadian Neurosurgical Society practice guidelines review group
- Books Received 171
- Book Reviews 171
- Calendar of Events 178
- Notes and Announcements 179
- Information for Authors xii
- Advertisers Index xliii

THE CANADIAN JOURNAL OF
Neurological Sciences
LE JOURNAL CANADIEN DES
Sciences Neurologiques

Editor/Rédacteur en chef

James A. Sharpe TORONTO, ON

Associate Editors/Rédacteurs associés

Laurence E. Becker TORONTO, ON

John P. Girvin LONDON, ON

John R. Wherrett TORONTO, ON

Past Editors

Robert G. Lee CALGARY, AB

Robert T. Ross WINNIPEG, MB

(founding editor)

Editorial Board/Conseil Scientifique

Harold P. Adams IOWA CITY, IA, USA

Jack P. Antel MONTREAL, QC

Pierre Duquette MONTRÉAL, QC

Peter J. Dyck ROCHESTER, MN, USA

Andrew A. Eisen VANCOUVER, BC

Max J. Findlay EDMONTON, AB

Julian T. Hoff ANN ARBOR, MI, USA

Renn Holness HALIFAX, NS

George Karpati MONTRÉAL, QC

Patrick L. McGeer VANCOUVER, BC

John H. Noseworthy ROCHESTER, MN, USA

C. Warren Olanow NEW YORK, NY, USA

William Pryse-Phillips ST. JOHNS, NF

Ali H. Rajput SASKATOON, SK

James T. Rutka TORONTO, ON

Shashi S. Seshia WINNIPEG, MB

Alan M. Smith MONTRÉAL, QC

Garnette R. Sutherland CALGARY, AB

Jean-Guy Villemure MONTRÉAL, QC

Douglas W. Zochodne CALGARY, AB

Book Review Editor / Rédacteur de critiques de livres

Warren P. Mason TORONTO, ON

News Editor/Rédacteur (nouvelles)

John W. Norris TORONTO, ON

Managing Director/Gérant directrice

Sally A. Gregg CALGARY, AB

Publications Committee/Comité de Rédaction

Pierre Langevin STE-FOY, QC

Donald Brunet KINGSTON, ON

Mark Hamilton CALGARY, AB

Andrew Kertesz LONDON, ON

The official journal of: / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des quatre associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is \$65 for members; \$75 for non-members in Canada; \$85 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students \$32.50 per annum (members); \$37.50 per annum (non-members). Single copies \$20 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 810, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: cjns@canjneurosci.org; Web Site: www.canjneurosci.org
COPYRIGHT © 1997 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*, *Current Awareness in Biological Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 65 \$ pour les membres; 75 \$ pour les non-membres au Canada; 85 \$ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 32,50 \$ par année (membres); 37,50 \$ par année (non-membres). Copie simple: 20 \$ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à *Journal Canadien des Sciences Neurologiques*, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 810, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail cjns@canjneurosci.org; Web Site: www.canjneurosci.org
DROITS D'AUTEUR © 1997: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice et Life Sciences*, *Current Awareness in Biological Sciences*.

Advertising representative/Représentant de publicité:

Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7
Tel (403) 229-9575 Fax (403) 229-1661


E-mail: cjns@canjneurosci.org

Web site: www.canjneurosci.org

Printer/Imprimeur:

McAra Printing Limited, 105, 2507 - 12th Street N.E.,
Calgary, Alberta T2E 7L5

ISSN 0317 - 1671



A
CHANCE
TO
CONTROL
PARTIAL
SEIZURES

SABRIL[®]
VIGABATRIN

Winner of the 1996
Prix Galien Canada
for Innovative Product

PAAB PMAC ©Reg. trade mark of Merrell Pharmaceuticals Inc., USA.
Used under licence by Hoechst Marion Roussel Canada Inc.,
Laval, Quebec H7L 4A8
SABR96016E

IMPRESSIVE EFFICACY¹ WHEN SABRIL[®] IS ADDED TO FIRST LINE TREATMENT

- Almost 50% of patients (n=333)[†], with mild to moderate partial epilepsy, became seizure-free²
- Significant increase in seizure control[‡] in 66% of patients³
- No negative effects on cognitive function to impair job performance or quality of life⁴

[†] Of the 333 patients who completed > 100 days of treatment (mean dose 2.6 ± 0.5 g/day)

[‡] ≥ 50% reduction in seizure frequency; N=31, at doses of 1-2 gm per day, duration of 8 weeks, as part of an initial, open phase study. However in clinical trials, Sabril reduced seizure frequency by 50% or more in approximately half of the patients studied.

Neurological function/visual disturbances should be monitored; used with caution in patients with a history of psychosis, in the elderly, in the renally impaired; there could be occupational hazards due to drowsiness; there may be a possible increase in seizures in some patients.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc.,
Laval, Quebec H7L 4A8
A member of the Hoechst Group

Hoechst 

For brief prescribing information see page x
<https://doi.org/10.1017/S0954579400021503> Published online by Cambridge University Press

Lamictal
Adjunctive Antiepileptic Therapy

Control over a wide with a low CNS



[†]Withdrawal rates ($\geq 0.6\%$): dizziness 2.4%, headache 1.3%, nausea 1.3%, blurred vision 1.1%, rash 1.1%, diplopia 0.7%, ataxia 0.6%. If there is any unexplained rash, fever, flu-like symptoms or worsening of seizure control, then hepatic, renal and clotting parameters should be monitored. See Product Monograph for recommendations when prescribing for geriatric patients and for patients with impaired renal and/or liver function. Serious skin-related events may be related to rapid initial titration of dosing and use of concomitant valproic acid.

[‡]As with most other AEDs, before prescribing LAMICTAL, refer to Product Monograph for possible drug interactions with other AEDs.


GlaxoWellcome

Glaxo Wellcome Inc.

®Registered trademark of The Wellcome Foundation Limited. Glaxo Wellcome Inc. licensed use.

PAAB
CCPP

range of seizure types, side-effect profile



Many patients with epilepsy – across a wide range of seizure types – are unsatisfactorily controlled with conventional therapies.¹ Now there's LAMICTAL, a novel antiepileptic drug (AED) that is chemically unrelated to all other AEDs in current use.^{1,2}

Clinical trials and worldwide experience in over 140,000 patients³ have shown that adjunctive therapy with LAMICTAL offers a wide range of activity in the management of epilepsy for patients who are not satisfactorily controlled by conventional therapies.¹⁻²⁴ In fact, LAMICTAL has been shown to render patients seizure-free^{4-6,25} or to reduce seizure frequency^{1,6,10,15-17,23,25} and severity in up to 65% of patients.^{1,6,16,23,25} LAMICTAL has demonstrated a more favourable CNS side-effect profile in healthy volunteers compared to phenytoin.²⁶ Incidence of somnolence was 13% for LAMICTAL compared to 12% for placebo in pooled results of four double-blind, placebo-controlled studies.⁷ Moreover, the majority of patients taking LAMICTAL will not experience unwanted CNS-related side effects.^{5†} More of your refractory patients will feel better on LAMICTAL.^{6,23}


LAMICTAL has activity across a wide range of seizure types. You can now offer your patients proven tolerability with a low CNS side-effect profile.[†] When faced with refractory patients, choose LAMICTAL – in 25-, 100- or 150-mg strengths – as your first add-on therapy.[†]

Lamotrigine
Lamictal[®]

NEW IN EPILEPSY




Vincent Van Gogh



Alexander the Great




Lord Byron



Charles Dickens


ONCE IT TOOK EXCEPTIONAL EFFORT OR EXTRAORDINARY LUCKILY, YOUR PATIENTS CAN NOW




Adapted from reference 1. Double-blind trial of placebo vs. TOPAMAX b.i.d. as adjunctive therapy in 181 patients with refractory partial onset epilepsy receiving one or two other AEDs. *p=0.013.

Improved control over a wide range of seizure types


- TOPAMAX is indicated as adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled with conventional therapy. There is limited information on the use of TOPAMAX in monotherapy at this time.
- High responder rate: 27% (200mg/day, n=45) and 47% (400mg/day, n=45) of patients experienced ≥ 50% reduction in partial seizures (16 week study)¹
- Effective control for patients with secondarily generalized tonic-clonic seizures: 36% of patients experienced a 100% reduction (200-600 mg, n=42, 16 week study)¹
- Unique three-way mechanism of action (Na⁺ channel blockade, GABA potentiation, glutamate antagonism)²



Joan of Arc



Alfred Nobel



George Frederick Handel



Fyodor Dostoyevsky

TALENT FOR PEOPLE WITH EPILEPSY TO SUCCEED. ENJOY LESS TAXING ALTERNATIVES.

- Generally well tolerated: Discontinuations due to adverse events were 10.6% at 200-400 mg/day compared to 5.8% in the placebo group (this appeared to increase at dosages above 400 mg/day)²
- No evidence of serious rash or aplastic anemia²
- Dosage adjustments to primary therapy are generally not required; patients on phenytoin showing clinical signs or symptoms of toxicity should have phenytoin levels monitored^{1,2}
- **Convenient BID dosing**


†As with other AEDs, please see prescribing information for complete information on drug interactions. A 1.5% (n=1715) incidence of kidney stones has been reported.² In one study (n=1200), 83% (15 of 18) of patients elected to continue therapy.¹ Ensure adequate hydration and avoid concomitant use with other carbonic anhydrase inhibitors.² *Trademark © Janssen-Ortho Inc. 1997

JANSSEN-ORTHO Inc.
19 Green Belt Drive
North York, Ontario M3C 1L9



Favourable side effect profile (the most common are CNS related)

	TOPAMAX 200-400 mg (n=113)	PLACEBO (n=216)
Somnolence	30.1	9.7
Dizziness	28.3	15.3
Ataxia	21.2	6.9
Psychomotor slowing	16.8	2.3
Speech disorders	16.8	2.3
Nervousness	15.9	7.4
Nystagmus	15.0	9.3
Paresthesia	15.0	4.6



TOPAMAX
topiramate

Helping patients make more of their lives

Introducing ^{Pr} **BETASERON**[®]

The first treatment for relapsing/remitting multiple sclerosis



For an overview of Betaseron
dial 1-800-422-1222, access code 400.

Clinical trials have shown that:

- *The frequency of exacerbations was reduced by approximately 30%¹*
- *Moderate and severe exacerbations were reduced by 50%¹*
- *Disease activity, as measured by MRI, was reduced significantly²*
- *There was a low incidence of serious side effects¹*
- *Patient education about common side effects such as injection-site reactions and flu-like symptoms is key to compliance*

Over 40,000 patients treated to date³



BETASERON[®]
 INTERFERON BETA-1b
 FOR SC INJECTION

Maintaining Independence

PRESCRIBING INFORMATION



ACTION AND CLINICAL PHARMACOLOGY

SABRIL (vigabatrin) is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the catabolism of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. The mechanism of action of vigabatrin is attributed to irreversible enzyme inhibition of GABA-T, and consequent increased levels of the inhibitory neurotransmitter, GABA. Decreased serum levels of SGOT (ALT) and SGPT (AST) have been observed during treatment with vigabatrin and may be the result of inhibition of these transaminases by vigabatrin. The clinical significance of these findings is unknown. The duration of effect of vigabatrin is thought to be dependent on the rate of GABA-T resynthesis rather than on the plasma concentration of vigabatrin.

Clinical Trials

In clinical trials, including double-blind, placebo-controlled studies involving 354 patients with drug-resistant complex partial seizures, vigabatrin reduced seizure frequency by 50% or more in approximately half of the patients studied.

In clinical trials involving children, the efficacy of vigabatrin was similar to that seen in adult patients with refractory partial seizures. In one study of 70 children with intractable infantile spasms, approximately 70% of the patients had a greater than 50% reduction in spasms. In this study, long-term response was observed in 75% of the children with symptomatic infantile spasms and 36% of the children with cryptogenic infantile spasms.

Pharmacokinetics

Vigabatrin is rapidly absorbed following oral administration and peak plasma concentrations are reached within two hours. Vigabatrin is widely distributed with an apparent volume of distribution slightly greater than total body water. The primary route of elimination is via the kidney, with little metabolic transformation occurring. Following a single dose, approximately 70% is excreted in the urine as unchanged drug within the first 24 hours post-dose. The plasma elimination half-life is approximately 5-8 hours in young adults and 12-13 hours in the elderly. In renal impairment the elimination is prolonged and the rate of renal clearance is directly related to creatinine clearance (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Vigabatrin does not induce the hepatic cytochrome P450 system nor is it extensively metabolized or plasma-protein bound. Administration of vigabatrin with food slightly reduces the rate, but not the extent of absorption.

INDICATIONS AND CLINICAL USE

SABRIL (vigabatrin) is indicated for the adjunctive management of epilepsy which is not satisfactorily controlled by conventional therapy. There is insufficient data on the usefulness of vigabatrin in monotherapy at this time. Vigabatrin should be used under close monitoring by a neurologist.

CONTRAINDICATIONS

SABRIL (vigabatrin) is contraindicated in pregnancy and lactation (see WARNINGS) and in patients with a known hypersensitivity to vigabatrin or to any components of the product.

WARNINGS

Neurotoxicity in Animals

Rat, Mouse and Dog: Safety studies carried out in the rat, mouse and dog at doses of 30 to 50 mg/kg/day and higher, caused dose- and time-dependent microvacuolation within certain white matter tracts of the brain (the cerebellum, reticular formation and thalamus in rodents and the columns of the fornix and optic tracts in dogs were most affected). The microvacuolation was caused by the separation of the outer lamellar sheath of myelinated fibres, a change characteristic of non-inflammatory intramyelinic edema.

In both the rat and dog (mouse was not tested), the intramyelinic edema was reversible after stopping the administration of vigabatrin; however, in the mouse and rat, residual changes consisting of swollen axons and mineralised microbodies were observed.

Monkey: In monkeys, the oral administration of 300 mg/kg/day for 16 months produced minimal microvacuolation with equivocal differences between treated and control animals. Low oral absorption of vigabatrin in the monkey resulted in an actual absorbed dose of 75 mg/kg/day. In spite of the poor absorption, cerebrospinal fluid (CSF) levels of vigabatrin in the monkeys were comparable to those seen in rats treated with 300 mg/kg/day; however, GABA levels in the CSF and the brain cortex in treated monkeys were not significantly different from untreated monkeys. This finding may explain the reason for the equivocal effects, since the intramyelinic edema associated with vigabatrin treatment appears to be to increased brain GABA levels.

Evoked Potentials

Evoked potentials in animals: In the dog, studies indicate that intramyelinic edema is associated with increased latencies in somatosensory and visual evoked potentials. Magnetic resonance imaging (MRI) changes also correlated with intramyelinic edema in the fornix, thalamus and hypothalamus.

Evoked potentials in man: No increased evoked potential latencies have been observed in man. Two hundred and twenty-one patients treated for 4-5 months showed no significant evoked potential latency changes at the end of treatment as compared to baseline. MRI results in man did not show the changes observed in dogs who had intramyelinic edema.

References:

- Grant SM, Heel RC. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy and Disorders of Motor Control. *Drugs. Adis International.* June 1991, Vol. 41 No. 6, pp. 889-926.
- Arzimanoglou AA, Dumas C, Chirardi L et al. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. *Epilepsia* 1995;36(53)
- Reynolds BH, Ring HA, Farr IN et al. Open, double-blind and long term study of vigabatrin in long term epilepsy. *Epilepsia* 1991;32(4):530-538.
- Doddrell CB, Arnett JL, Sommerville KW, Sussman NM. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. *Epilepsia* 1995;36(2):164-173.

© Registered trade mark of Menell Pharmaceuticals Inc., USA.

Used under licence by Hoechst Marion Roussel Canada Inc., Laval, Quebec H7L 4A8

Postmortem neuropathological changes seen in 11 patients who were treated with vigabatrin (mean duration of treatment was 28 months, and the longest treatment was 6 years) showed no myelin vacuolation in the white matter that was considered to be outside of the control range.

Although clinical trials have not revealed the type of neurotoxicity seen in animal studies, because of increased CSF GABA levels observed in humans, it is recommended that patients treated with vigabatrin be closely observed for adverse effects on neurological function, with special attention to visual disturbance.

Use in Pregnancy and Lactation: In a teratology study in the rabbit a dose-related incidence, 2% and 9%, of cleft palate was observed at doses of 150 and 200 mg/kg/day, respectively.

In animal reproductive studies neurohistopathology was not performed on the fetuses, therefore it is not known whether micro-vacuolation occurred in utero. The possibility that microvacuolation or other neurotoxicity may occur in human fetuses cannot be discarded.

PRECAUTIONS

Use in Patients with a History of Psychosis Behavioural disturbances such as aggression and psychotic episodes have been reported following initiation of vigabatrin therapy. A history of abnormal behaviour or psychosis appears to be a predisposing factor for such reactions, therefore treatment in such patients should be initiated cautiously at low doses and with frequent monitoring.

Use in the Elderly and in Patients with Renal Impairment Vigabatrin is eliminated via the kidney and caution should be exercised when administering the drug to elderly patients and to patients with renal impairment (see DOSAGE AND ADMINISTRATION).

Use in Patients with Myoclonic Seizures As with other antiepileptic drugs, some patients may experience an increase in seizure frequency with vigabatrin. Patients with myoclonic seizures may be particularly liable to this effect.

Discontinuation of Therapy As with other antiepileptic drugs, abrupt discontinuation may lead to rebound seizures. If a patient is to be withdrawn from vigabatrin treatment, it is recommended that this be done gradually by reducing the dose over a 2 to 4 week period if possible.

Drug Interactions A gradual reduction of about 20% in plasma phenytoin concentration has been observed following add-on therapy with vigabatrin. The mechanism whereby this occurs is unknown. Limited data from clinical trials suggest that increasing the phenytoin dose to compensate may not be necessary.

Occupational Hazards Patients with uncontrolled epilepsy should not drive or handle potentially dangerous machinery. During clinical trials, the most common adverse reactions observed were drowsiness and fatigue. Patients should be advised to refrain from activities requiring mental alertness or physical coordination until they are sure that vigabatrin does not affect them adversely.

ADVERSE REACTIONS

SABRIL (vigabatrin) is generally well tolerated in epileptic patients. Adverse events are mainly CNS-related and probably a secondary consequence of increased GABA levels caused by vigabatrin. The safety of vigabatrin was evaluated in 2081 epileptic patients treated in clinical trials. The relationship of adverse events to vigabatrin therapy was not clearly established as patients were taking other antiepileptic drugs concomitantly. The most frequently reported adverse events were somnolence (12.5%), fatigue (9.2%), and weight gain (5.0%).

The following adverse events were observed in more than 1% of patients:

Adverse Events Reported By More Than 1% of Patients		
Body System/ Adverse Event	Number of Patients	Incidence n=2081
Nervous		
somnolence	261	12.5
headache	80	3.8
dizziness	79	3.8
nervousness	56	2.7
depression	52	2.5
memory disturbances	47	2.3
diplopia	46	2.2
aggression	42	2.0
ataxia	39	1.9
vertigo	39	1.9
hyperactivity	37	1.8
vision abnormal	34	1.6
confusion	29	1.4
insomnia	26	1.3
impaired concentration	25	1.2
personality disorder	23	1.1
agitation	21	1.0
Digestive		
abdominal pain	34	1.6
constipation	29	1.4
vomiting	28	1.4
nausea	28	1.4
Body as a Whole		
fatigue	192	9.2
weight gain	104	5.0
asthenia	23	1.1

Adverse events reported with a frequency of less than 1% include: anxiety, emotional lability, behavioural disturbances including psychosis, irritability, tremor, abnormal gait,

speech disorder, increased appetite, and dyspepsia.

As with other antiepileptic drugs, some patients may experience an increase in seizure frequency with vigabatrin treatment (see PRECAUTIONS).

Laboratory data indicate that vigabatrin treatment does not lead to renal or hepatic toxicity. Chronic treatment with vigabatrin may be associated with a slight decrease in hemoglobin, which rarely attains clinical significance.

Pediatric Safety Safety data is available in 299 children, aged 2 months to 16 years (1 patient was 18 years of age), participating in clinical trials with vigabatrin. Relationship of adverse events to vigabatrin therapy was not clearly established as children were taking other antiepileptic drugs concomitantly.

The most frequent adverse event observed in children was "hyperactivity" (reported as hyperkinesia 7.7%, agitation 2.3%, excitation 0.3% or restlessness 0.7%), which was observed in 11.0% of children, an incidence higher than that seen in adults. Other commonly reported adverse events were somnolence (8.0%) and weight gain (3.0%).

The following adverse events were reported in children with a frequency greater than 1%:

Adverse Events Reported By More Than 1% of Pediatric Patients		
Body System/ Adverse Event	Number of Patients	Incidence n=299
Nervous		
somnolence	24	8.0
hyperkinesia	23	7.7
aggression	8	2.7
insomnia	8	2.7
agitation	7	2.3
ataxia	7	2.3
emotional lability	3	1.0
headache	3	1.0
increased seizures	3	1.0
Digestive		
vomiting	6	2.0
nausea	3	1.0
increased saliva	3	1.0
Body as a Whole		
weight gain	9	3.0
fatigue	8	2.7
hypotonia	3	1.0

SYMPTOMS AND TREATMENT OF OVERDOSAGE

There is no specific antidote. The usual supportive measures should be employed.

Two cases of SABRIL (vigabatrin) overdose have been reported. In the first case, the patient accidentally took a dose of 14 g daily for 3 days and transient vertigo and tremor were reported. In the second case, an 18-year-old female took 30 g of vigabatrin and 250 mg of chlorazepate in a suicide attempt. The patient was admitted to hospital in a state of coma which lasted four days; however, the coma was considered to be due to the chlorazepate rather than vigabatrin. The patient recovered without sequelae.

DOSAGE AND ADMINISTRATION

SABRIL (vigabatrin) is intended for oral administration once or twice daily and may be taken with or without food. Sabril should be added to the patient's current antiepileptic therapy.

Instructions to the patient on the use of SABRIL are provided in the INFORMATION FOR THE CONSUMER section.

Adults The recommended starting dose is 1 g/day, although patients with severe seizure manifestations may require a starting dose of up to 2 g/day. The daily dose may be increased or decreased in increments of 0.5 g depending on clinical response and tolerability. The optimal dose range is between 2-4 g/day. Increasing the dose beyond 4 g/day does not usually result in improved efficacy and may increase the occurrence of adverse reactions.

Children The recommended starting dose in children is 40 mg/kg/day, increasing to 80 - 100 mg/kg/day depending on response. Therapy may be started at 0.5 g/day, and raised by increments of 0.5 g/day weekly depending on clinical response and tolerability.

Elderly and Renally Impaired Patients Vigabatrin is almost exclusively eliminated

Bodyweight	Daily Dose	No. Tablets/Day
10 - 15 kg	0.5 - 1 g/day	1 - 2 tablets/day
16 - 30 kg	1 - 1.5 g/day	2 - 3 tablets/day
31 - 50 kg	1.5 - 3 g/day	3 - 6 tablets/day
> 50 kg	2 - 4 g/day	4 - 8 tablets/day

via the kidney and, therefore, caution should be exercised when administering the drug to the elderly, and more particularly to patients with creatinine clearance less than 60 mL/min. It is recommended that such patients be started on a lower dose of vigabatrin and observed closely for adverse events such as sedation and confusion.

AVAILABILITY OF DOSAGE FORMS

Tablets

Each SABRIL (vigabatrin) 500 mg tablet is white to off-white film-coated, oval biconvex, and imprinted "SABRIL" on one side. SABRIL is available in HDPE bottles containing 100 tablets.

Product Monograph available on request.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc.,
Laval, Quebec H7L 4A8
A member of the Hoechst Group



UN
ESPOIR
POUR LA
MAÎTRISE
DES CRISES
PARTIELLES



SABRIL[®]
VIGABATRINE

Gagnant du prix Galien
Canada 1996 à titre de
produit le plus innovateur
de l'année

CCPP ACIM SABR96016F

© Marque déposée de Merrell Pharmaceuticals Inc., É.-U.,
utilisée sous licence par Hoechst Marion Roussel Canada Inc.,
Laval (Québec) H7L 4A8

Pour documentation voir page x.

SABRIL[®] DONNE DES RÉSULTATS IMPRESSIONNANTS¹ LORSQU'IL EST AJOUTÉ AU TRAITEMENT DE PREMIER RECOURS

- Maîtrise complète des crises chez près de 50 % des patients souffrant d'épilepsie partielle légère ou modérée (n = 333)^{†2}
- Augmentation significative[†] de la maîtrise des crises[‡] chez 66 % des patients³
- Aucun effet négatif sur la fonction cognitive pouvant nuire au rendement au travail ou à la qualité de vie du patient⁴

[†] Parmi 333 patients ayant reçu un traitement > 100 jours (dose moyenne : 2,6 ± 0,5 g/jour)

[‡] Réduction ≥ 50 % de la fréquence des crises. Trente et un patients ont reçu des doses de 1 à 2 g par jour pendant huit semaines au cours de la phase ouverte initiale d'un essai clinique. Lors d'autres essais, l'administration de Sabril[®] a toujours entraîné une réduction de > 50 % de la fréquence des crises chez environ la moitié des patients.

On devra assurer une surveillance du patient en présence de troubles neurologiques ou visuels. Administrer avec prudence chez les patients qui présentent des antécédents de psychose, les personnes âgées et les patients souffrant d'insuffisance rénale. La somnolence est susceptible d'accroître le risque d'accidents du travail. La vigabatrine peut entraîner une augmentation de la fréquence des crises chez certains patients.

XI

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc.,
Laval (Québec) H7L 4A8
Une société du Groupe Hoechst

Hoechst 

Lorsque la phénytoïne ou la carbamazépine ne réussissent pas à procurer une maîtrise adéquate des crises partielles chez l'adulte.

Sur la liste de médicaments du Québec

AJOUTER NEURONTIN

Aucune interaction pharmacocinétique avec les anticonvulsants traditionnels n'a été observée avec Neurontin. Il est par conséquent facile de l'utiliser comme traitement adjuvant avec les antiépileptiques existants¹.

 **NEURONTIN** *
(capsules de gabapentine)

Facile à utiliser comme adjuvant

Neurontin est indiqué comme traitement d'appoint pour les patients dont l'état épileptique n'est pas bien maîtrisé par les traitements traditionnels. Les effets secondaires les plus courants qui n'ont pas été observés à une fréquence équivalente chez les patients sous placebo sont les suivants : somnolence, étourdissements, ataxie, fatigue, nystagmus et tremblements. Étant donné que Neurontin était administré le plus souvent en association avec d'autres antiépileptiques, il était impossible de déterminer à quel(s) agent(s) les effets secondaires étaient associés.


 **PARKE-DAVIS**

Scarborough, Ontario M1L 2N3
*M. de comm. Warner-Lambert Company, Parke-Davis
Division, Warner-Lambert Canada Inc., usager aut.

Référence : 1. *The Lancet* 1994;343:89-91.



For brief prescribing information
see pages xxiv, xl.



**MIGRAINE
RELIEF
BEGINS IN
FIFTEEN
MINUTES¹**

New [®]*Imitrex*[®] Nasal Spray* starts to work
in half the time of our own [®]*Imitrex*[®] tablets^{1**}

- 15 minute onset of action vs. 30 minutes with *Imitrex*[®] tablets¹
- Efficacy similar to *Imitrex*[®] tablets^{1†}
- Generally well tolerated^{1-3††}
- Easy to use, convenient single dose device^{†††}

* sumatriptan nasal spray (20 mg). *Imitrex*[®] Nasal Spray is available in 5 mg and 20 mg doses. 5 mg is the minimum effective dose of *Imitrex*[®] Nasal Spray. Optimal rates of headache relief are achieved with the 20 mg dose.¹

** sumatriptan succinate (100 mg tablets)

¹ *Imitrex*[®] is a selective 5-HT₁ receptor agonist. *Imitrex*[®] is indicated for the relief of migraine attacks with or without aura. Contraindicated in patients with ischaemic heart disease, angina pectoris including Prinzmetal angina (coronary vasospasm), previous myocardial infarction and uncontrolled hypertension. There is no experience in patients with recent cerebrovascular accidents or cardiac arrhythmias (especially tachycardias). Therefore the use of *Imitrex*[®] in these patients is not recommended. For patient selection, please consult the Product Monograph of *Imitrex*[®] for detailed safety information.¹

^{††} Adverse event profile similar to placebo – except for a higher incidence of taste disturbance.¹⁻³

^{†††} No priming, one spray into one nostril.

GlaxoWellcome

PAAR
CCPP

 **IMITREX[®]**
SUMATRIPTAN NASAL SPRAY
A faster way back.™



Lamictal
Traitement antiépileptique d'appoint

La maîtrise d'un vaste éven un profil discret d'effets



†Taux d'abandon ($\geq 0,6\%$) : étourdissements 2,4 %, céphalées 1,3 %, nausées 1,3 %, vision trouble 1,1 %, éruptions cutanées 1,1 %, diplopie 0,7 %, ataxie 0,6 %. En présence d'éruption cutanée inexplicée, de fièvre, de symptômes pseudo-grippaux, ou de diminution de la maîtrise des crises, il faut surveiller les paramètres hépatiques, rénaux ou de coagulation. Voir dans la monographie du produit les recommandations chez les patients gériatriques et en cas d'atteinte rénale ou hépatique. De sérieux incidents cutanés peuvent être causés par un ajustement posologique initial rapide et l'emploi concomitant d'acide valproïque.

‡Comme avec la plupart des autres antiépileptiques, avant de prescrire LAMICTAL, vérifier dans la monographie du produit les risques d'interaction médicamenteuse avec d'autres antiépileptiques.


GlaxoWellcome

Glaxo Wellcome Inc.
Bureau d'affaires du Québec

®Marque déposée de The Wellcome Foundation Limited, Glaxo Wellcome Inc., usager inscrit.

PAAB
CCPP

tail de types de crises avec secondaires sur le SNC



De nombreux patients souffrant d'épilepsie – dans un vaste éventail de types de crises – ne sont pas contrôlés de façon satisfaisante par les traitements conventionnels¹. Maintenant, il y a **LAMICTAL, un nouvel antiépileptique inédit** sans parenté chimique avec aucun autre antiépileptique actuel^{1,2}.

Les essais cliniques et l'expérience mondiale acquise chez plus de 140 000 patients³ ont montré qu'**en traitement d'appoint, LAMICTAL offre une activité étendue dans le traitement de l'épilepsie** chez les patients qui ne sont pas contrôlés de façon satisfaisante avec les traitements conventionnels¹⁻²⁴. En fait, LAMICTAL a supprimé les crises^{4,6,25} ou diminué leur fréquence^{1,6,10,15-17,23,25} et leur gravité chez jusqu'à 65 % des patients^{1,6,16,23,25}. Chez des volontaires en santé, LAMICTAL a présenté **un profil d'effets secondaires sur le SNC plus favorable** que la phénytoïne²⁶. L'incidence de somnolence a été de 13 % pour LAMICTAL par rapport à 12 % pour le placebo dans les résultats combinés de quatre études à double insu contrôlées par placebo⁷. De plus, la plupart des patients sous LAMICTAL n'éprouveront pas d'effets indésirables qui affectent le SNC^{5†}. Un plus grand nombre de vos patients réfractaires se sentiront donc mieux sous LAMICTAL^{6,23}.

LAMICTAL exerce une activité dans un vaste éventail de types de crises. **Vous pouvez maintenant offrir à vos patients un médicament caractérisé par une tolérabilité éprouvée et un profil discret d'effets indésirables sur le SNC†**. Pour vos patients réfractaires, choisissez LAMICTAL – en 25, 100 ou 150 mg – comme votre premier traitement d'appoint[†].

lamotrigine
Lamictal®

Voici MIGRANAL en

Un agoniste des récepteurs 5-HT₁, qui agit rapidement et



Agoniste des récepteurs 5-HT₁

- MIGRANAL soulage la migraine et les symptômes connexes¹.
- L'administration par voie nasale permet de contourner le tractus gastro-intestinal.

Pour un soulagement rapide

- On peut prendre MIGRANAL à n'importe quel stade de la migraine¹.
- La réponse clinique commence à se manifester en moins de 30 minutes¹.
- Jusqu'à 70 % des migraines sont soulagées 4 heures après l'administration de MIGRANAL (n = 105)^{2†}.

Pour un soulagement durable^{††}

- Longue demi-vie : 10 heures¹
- Pas de réapparition de la migraine chez 85 % des répondeurs au cours des 24 heures suivant l'administration de MIGRANAL (n = 73)²
- Par conséquent, MIGRANAL peut permettre d'éviter le renouvellement fréquent de la dose, la prise de médicaments d'urgence, ainsi que les coûts qui s'y rattachent.

◇ Pour de meilleurs résultats, entreprendre le traitement dès les premiers signes ou symptômes d'une crise migraineuse.

† Soulagement = disparition complète ou atténuation de la douleur modérée ou grave

†† Jusqu'à 24 heures avec une seule dose de 2 mg

vaporisateur nasal

qui offre un soulagement durable de la migraine



Généralement bien toléré lors des essais cliniques¹

- Les effets indésirables les plus courants étaient transitoires, spontanément résolutifs et peut-être imputables à la voie d'administration^{2,3}. La rhinite (incidence de 25 %) comprend : rhinite, rhinorrhée, congestion nasale, sécheresse et oedème de la muqueuse nasale et éternuements en rafale. Parmi les autres effets secondaires observés, mentionnons les nausées (9 %), les perturbations gustatives (7 %) et les vomissements (4 %).

MIGRANAL est contre-indiqué chez les patients prédisposés aux réactions angiospastiques. Veuillez consulter les renseignements posologiques pour obtenir plus de détails.



MIGRANAL[®]
(mésylate de dihydroergotamine en vaporisateur nasal)
Soulagement rapide et durable de la migraine

*Marque déposée

 **SANDOZ**

SANDOZ CANADA INC.
Dorval (Québec) H9R 4P5

MIG-96-10-3501F

CCPP MEMBRE AC.I.M.

*EEG and PSG
instrumentation
made easy with
the new
Grass[®] Neurodata
System*



32 Channel Model 15 Neurodata System. Shown with optional PC.

The most important building block of an advanced EEG or PSG system is the amplifier system. And Grass amplifiers are known the world over to be the very best. Noise free. Stable. Reliable.

The new Model 15 system continues the great Grass tradition of quality while adding important new functions including an electrode test function, a built in calibrator, and an advanced montage card electrode switching system.

And with the Grass Windows program—supplied free with each Model 15—all amplifier and calibrator functions can be controlled by your computer.

These remarkable features make the new Grass Model 15 Amplifier System the logical choice of EEG and PSG instrumentation engineers.

Phone, fax or E-mail for complete details.



**Grass Instrument
Division**
Astro-Med[®], Inc.

Astro-Med, Inc., 648 rue Giffard, Longueuil, Québec J4G 1T8
Tel. (514) 651-7973 • Fax (514) 651-8987
Toll-Free 1-800-565-2216 (Canada Only)

E-mail: 104544.343@compuserve.com Web Site: <http://www.astro-med.com>

*Sales and Service Centers throughout the U.S., Canada
and Europe. Dealers located throughout the world.*

**1997 NORTH AMERICAN
STROKE MEETING**

**Clinical Aspects of Stroke
Diagnosis and Treatment**

**October 16 - 17, 1997
Montreal, Quebec, Canada**


The focus of this conference is to educate physicians, surgeons and other health professionals in clinical aspects of stroke, and the enhancement of their skills in diagnosing, treating and managing patients with stroke.

Topics

- Clinical Trials
- Long Term Stroke Prevention
- Cerebral Angioplasty
- Nutrition and Swallowing
- Acute Cerebral Ischemia
- Thrombolysis in Acute Stroke
- Hemorrhagic Stroke
- Ultrasound in Cerebrovascular Disease
- Organized Stroke Care

For meeting information please contact Ms. Kimberly Anderson at the CCNS (403) 229-9544 or Ms. Thelma Edwards, R.N., National Stroke Association at (303) 649-9299 ext. 919 for additional information

Take the Migranal Challenge!



FACT: 50% of migraines last 24 hours¹

FACT: Migranal offers up to 24 hours of relief with a single 2 mg dose²

Prove it to yourself.

- Obtain valuable feedback from your own patients
- Request your free Migranal patient self-assessment package today!

MIGRANAL[®]
(dihydroergotamine mesylate nasal spray)

Fast migraine relief that lasts.

1. O'Brien B, Goeree R et al. Int J Epid 1994;23(5):1020-1025.
2. Migranal Product Monograph, 1996, Sandoz Canada Inc.
3. Gallagher RM, Ventura D, DiSerio FJ et al. Arch of Neurol 1996;53:1285-1291.
4. Ziegler D, Ford R, Kriegler J et al. Neurology 1994;44:447-453.



Migranal is indicated for the treatment of migraine headache, with or without aura, in adults. Migranal is contraindicated in patients predisposed to vasospastic reactions.

Most common adverse events were transient and self-limiting, and may be attributable to the route of administration^{3,4}: Rhinitis (25% incidence) reported as rhinitis, rhinorrhea, nasal/nose congestion, dryness, edema and excessive sneezing; nausea (9%), taste disturbance (7%) and vomiting (4%).

Product Monograph available upon request.

Simply photocopy this page and send by Fax: 1-800-524-4482

Space for address stamp

Name: _____

Address: _____

Postal Code: _____ Tel: _____



- Please send me a free Migranal Challenge self-assessment package
- Please have a representative arrange to visit with more information about Migranal

 **NOVARTIS**

Novartis Pharmaceuticals Canada Inc.
Manufactured by Sandoz Canada Inc.
Dorval, Québec H9R 4P5


PAAB MEMBER 

MIG-97-04-3556E
* Registered trademark

DU NOUVEAU À PROPOS DE L'ÉPILEPSIE




Vincent Van Gogh



Alexandre le Grand




Lord Byron



Charles Dickens


NAGUÈRE ENCORE, LA RÉUSSITE EXIGEAIT D'UN ÉPILEPTIQUE HEUREUSEMENT POUR VOS PATIENTS, IL EXISTE




Extrait de référence N° 1. Étude en double aveugle avec placebo contre TOPAMAX b.i.d. comme traitement d'appoint, portant sur 181 patients atteints d'épilepsie partielle réfractaire et recevant une ou deux autres médications antiépileptiques. *p = 0,013.

Contrôle amélioré d'une plus grande variété de types de crises.


- TOPAMAX est indiqué comme traitement d'appoint pour toutes les épilepsies réfractaires aux traitements conventionnels. À l'heure actuelle, les données sur l'utilisation de TOPAMAX comme traitement unique demeurent limitées.
- Taux élevé de répondants : 27 % (200 mg/jour, n = 45) et 47 % (400 mg/jour, n = 45) des patients ont manifesté une réduction des crises d'épilepsie partielle ≥ 50 % (étude d'une durée de 16 semaines)¹
- Contrôle efficace pour les patients souffrant de crises toniques-cloniques secondaires généralisées : 36 % des patients ont manifesté une réduction de 100 % (200-600 mg, n = 42, étude portant sur 16 semaines)¹
- Triple mécanisme d'action unique : blocage des canaux sodiques, activation de l'acide gamma-aminobutyrique, antagonisme du glutamate)²



Jeanne d'Arc



Alfred Nobel



George Frederick Handel



Fyodor Dostoyevsky


DES EFFORTS EXCEPTIONNELS OU UN TALENT EXTRAORDINAIRE. MAINTENANT DES SOLUTIONS PLUS ACCESSIBLES.

- Généralement bien toléré: les interruptions entraînées par des réactions adverses étaient de 10,6 % pour les doses journalières de 200 à 400 mg, comparé à 5,8 % pour le groupe placebo (cela semblerait augmenter pour les doses journalières supérieures à 400 mg)²
- Aucune preuve d'éruption cutanée sérieuse ni d'anémie aplasique²
- Il n'est généralement pas nécessaire de changer le dosage des médications principales; les patients prenant de la phénytoïne et manifestant des signes ou symptômes de toxicité devraient faire contrôler leurs niveaux de phénytoïne¹²
- **Dosage commode BID**

[†]Comme pour les autres traitements antiépileptiques, veuillez vous reporter aux renseignements thérapeutiques pour plus de détails concernant les interactions médicamenteuses. On a rapporté l'occurrence de 1,5 % (n = 1715) de calculs rénaux². Dans une étude (n = 1200), 83 % des patients (15 sur 18) ont choisi de continuer le traitement¹. Assurer un taux d'hydratation adéquat et éviter l'utilisation parallèle d'autres inhibiteurs de l'anhydrase carbonique².

Profil favorable des effets secondaires (les plus courants affectent le SNC)

	TOPAMAX 200-400 mg (n = 113)	PLACEBO (n = 216)
Somnolence	30,1	9,7
Étourdissements	28,3	15,3
Ataxie	21,2	6,9
Ralentissement psychomoteur	16,8	2,3
Troubles de la parole	16,8	2,3
Nervosité	15,9	7,4
Nystagmus	15,0	9,3
Paresthésie	15,0	4,6



TOPAMAX
topiramate

Aide vos patients à mieux tirer parti de leur vie

When phenytoin or carbamazepine
fail to provide adequate seizure control
in adult partial seizures...

Available as N.F.B.
in Ontario

ADD NEURONTIN

No pharmacokinetic drug interactions with standard anticonvulsants have been observed with Neurontin. Thus, it is easy to use as adjunctive therapy with existing antiepileptic drugs.¹

NEURONTIN^{*}
(gabapentin capsules)

Easy to add-on

Neurontin is indicated as adjunctive therapy for the management of patients who are not satisfactorily controlled by conventional therapy. The most commonly observed adverse events not seen at an equivalent frequency in placebo-treated patients were somnolence, dizziness, ataxia, fatigue, nystagmus and tremor. Since Neurontin was administered most often in combination with other antiepileptic agents, it was not possible to determine which agent(s) was associated with adverse events.

PARKE-DAVIS

Scarborough, Ontario M1L 2N3
*T.M. Warner-Lambert Company, Parke-Davis Division,
Warner-Lambert Canada Inc., auth. user.

Reference: 1. *The Lancet* 1994;343:89-91.

PMAC

PAAB
CCPP

Epilepsy is the last thing on these active minds... Tegretol CR at work!



Effective seizure control

- Significant clinical benefit with excellent control of epileptic seizures.^{1,2}

Impressive safety profile

- Stable carbamazepine plasma levels can lead to a lower minimal incidence of concentration - dependent side effects than regular Tegretol.⁴
- A high degree of tolerability.^{2*}


Achieve and maintain good seizure control with a low incidence of concentration - dependent side effects.⁴

One of the most commonly reported side effects with carbamazepine is drowsiness. This reaction usually occurs only during the initial phase of therapy⁴ and can be minimized by using controlled-release carbamazepine. (PrTegretol® CR).³

Carbamazepine is not effective in controlling absence, myoclonic or atonic seizures, and does not prevent the generalization of epileptic discharge. Moreover, exacerbation of seizures may occasionally occur in patients with atypical absences.⁴

*See Product Monograph for important warnings prior to prescribing.

Diurnal plasma concentration curves between regular Tegretol and Tegretol CR in children (n=25).³



PrTegretol® CR versus regular PrTegretol®

- Equivalent and/or improved efficacy and tolerability.⁶
- May significantly reduce seizure frequency.⁷
- Reduced interference with cognitive function.⁵

Pr Tegretol® CR
(controlled release carbamazepine)
and
Pr Tegretol® Suspension
(carbamazepine)

**HELPING EPILEPSY PATIENTS REACH
THEIR FULL POTENTIAL**

Geigy

Pharmaceuticals

Mississauga, Ontario L5N2W5 or
Dorval, Quebec H9S 1B1

PAAB
CCPP
PMAC
ACIM
G-96070E



in

EPILEPSY

**treatment goal is
complete control**

Impressive degree
of complete seizure control¹

Frisium is a "remarkably
effective and [generally] safe
add-on anti-epileptic drug"¹

Effective in all seizure types,
in adults and children alike²

Once-daily dosage,
preferably at bedtime[†]

W I D E - R A N G E



 **Frisium** (clobazam)

Once a Day[†]

[†] Daily dose can be divided for some patients

Frisium is indicated as adjunctive therapy in epileptic patients not adequately stabilized with their current anticonvulsant therapy. As with all benzodiazepines, patients (particularly geriatrics) should be cautioned accordingly. Most frequent adverse effects (> 1%) include drowsiness, dizziness, fatigue, ataxia, weight gain, nervousness, behaviour disorder, hostility and blurred vision.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc.,
Laval, Quebec H7L 4A8
A member of the Hoechst Group

Hoechst 

©Reg. trade mark of Hoechst AG, Germany

  FRI 96012 E

xxviii For brief prescribing information see page xli.